Ocrelizumab
- Generic Name
- Ocrelizumab
- Brand Names
- Ocrevus
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 637334-45-3
- Unique Ingredient Identifier
- A10SJL62JY
- Background
Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-humanized CD20 antibodies such as rituximab, ...
- Indication
用于治疗复发型多发性硬化症（MS）。
- Associated Conditions
- Clinically Isolated Syndrome (CIS), Primary Progressive Multiple Sclerosis (PPMS), Relapsing Multiple Sclerosis (RMS), Relapsing Remitting Multiple Sclerosis (RRMS), Active Secondary Progressive Multiple Sclerosis (SPMS)
- Associated Therapies
- -
A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis
- First Posted Date
- 2019-08-30
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 23
- Registration Number
- NCT04075266
- Locations
- 🇺🇸
Boston Childrens Hospital, Boston, Massachusetts, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸University of Colorado Denver Childrens Hospital Rocky Mountain MS Center, Aurora, Colorado, United States
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2019-07-29
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1000
- Registration Number
- NCT04035005
- Locations
- 🇵🇱
Galen Clinic, Lublin, Poland
🇺🇸HonorHealth Neurology, Scottsdale, Arizona, United States
🇺🇸Multiple Sclerosis Center of California, Newport Beach, California, United States
A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 134
- Registration Number
- NCT03972306
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸University of Massachusetts Medical School, Worcester, Massachusetts, United States
🇺🇸University of Texas at Houston; Neurology, Houston, Texas, United States
Ocrelizumab Effects on the Metabolome in MS
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 25
- Registration Number
- NCT03873389
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Short-term B-cell Depletion in Relapsing Multiple Sclerosis
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 10
- Registration Number
- NCT03853746
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Efficacy of Ocrelizumab in Autoimmune Encephalitis
- First Posted Date
- 2019-02-11
- Last Posted Date
- 2021-10-19
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 3
- Registration Number
- NCT03835728
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
Real-world Data of Ocrelizumab in Multiple Sclerosis in LATAM
- Conditions
- Interventions
- First Posted Date
- 2018-12-24
- Last Posted Date
- 2019-08-09
- Lead Sponsor
- Hospital Italiano de Buenos Aires
- Target Recruit Count
- 100
- Registration Number
- NCT03784547
- Locations
- 🇦🇷
Juan Ignacio Rojas, Buenos Aires, Argentina
🇦🇷Edgard Carnero, Buenos Aires, Argentina
Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714
- Conditions
- Interventions
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 51
- Registration Number
- NCT03691077
- Locations
- 🇫🇷
Hôpital Saint-Antoine - Service de Neurologie, Paris, France
This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1500
- Registration Number
- NCT03599245
- Locations
- 🇦🇷
Centro de Especialidades Neurológicas y Rehabilitación - CENyR, Buenos Aires, Argentina
🇧🇷Instituto de Neurologia de Curitiba, Curitiba, PR, Brazil
🇧🇪UZ Antwerpen, Edegem, Belgium
Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis
- First Posted Date
- 2018-07-20
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1710
- Registration Number
- NCT03593590
- Locations
- 🇧🇪
Revalidatie en MS Centrum, Overpelt, Belgium
🇧🇬Multiprofile Hosp. for Active Treatment;National Cardiology Hosp., Sofia, Bulgaria
🇧🇬"City Clinic UMHAC" EOOD, Sofia, Bulgaria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.